Combretastatin A4

Target: This ligand targets tubulin at the colchicine-binding site in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for tubulin at the colchicine-binding site. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings tubulin at the colchicine-binding site into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Microtubule-Targeted PROTACs: Combretastatin A4 can serve as a high-affinity ligand to recruit E3 ligases in PROTAC designs, enabling selective degradation of microtubule-associated targets. By conjugating this ligand to an E3-binding moiety, researchers can probe whether induced proximity disrupts microtubule dynamics and drives ubiquitin-dependent proteolysis.

• Cytoskeleton Degradation Studies: Use Combretastatin A4-based chimeras to investigate how targeted protein loss affects cytoskeletal organization. PROTAC-mediated degradation can help distinguish degradation-driven phenotypes from reversible binding effects, supporting mechanistic studies of mitotic arrest, spindle integrity, and downstream signaling pathways linked to microtubule function.

• Mitotic Checkpoint Mechanism: Combretastatin A4 can be leveraged in PROTAC frameworks to interrogate mitosis-specific dependencies. Degrading relevant microtubule regulators through induced proximity allows researchers to map temporal requirements for protein turnover during spindle assembly, chromosome segregation, and checkpoint activation, providing experimentally testable links between degradation kinetics and mitotic outcomes.

• Structure–Activity Optimization: Combretastatin A4 is suitable for systematic PROTAC engineering to optimize linker length, attachment site, and stereochemical presentation. Researchers can evaluate how these variables influence ternary complex formation, ubiquitination efficiency, and degradation potency, thereby refining design rules for microtubule-targeting degraders.

Combretastatin A4 is a microtubule/tubulin ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Combretastatin A4 is characterized by phenol or alcohol functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.